New asthma drug candidate IBI3002 begins first human safety tests

NCT ID NCT06947408

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested the safety of a new drug called IBI3002 in 40 healthy volunteers and 20 people with asthma. Participants received either the drug or a placebo, and researchers monitored for side effects. The goal was only to check if the drug is safe enough to study further, not to see if it improves asthma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IBI3002

What this could lead to

If safe, this could lead to larger studies testing whether IBI3002 helps control asthma symptoms.

What could go wrong

This is a very early Phase 1 safety trial with only 44 participants. It is not designed to test if the drug works for asthma, and many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • China-japan Friendship Hosipital

    Beijing, Beijing Municipality, 100192, China